- Home
- INSI vs CLLS Comparison
INSI vs CLLS Comparison
Compare INSI & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSI
- CLLS
- Stock Information
- Founded
- INSI 1971
- CLLS 1999
- Country
- INSI United States
- CLLS France
- Employees
- INSI N/A
- CLLS 216
- Industry
- INSI Investment Managers
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- INSI Finance
- CLLS Health Care
- Exchange
- INSI Nasdaq
- CLLS Nasdaq
- Market Cap
- INSI 183.7M
- CLLS 148.1M
- IPO Year
- INSI N/A
- CLLS 2007
- Fundamental
- Price
- INSI $17.08
- CLLS $1.48
- Analyst Decision
- INSI
- CLLS Buy
- Analyst Count
- INSI 0
- CLLS 3
- Target Price
- INSI N/A
- CLLS $7.00
- AVG Volume (30 Days)
- INSI 22.0K
- CLLS 235.1K
- Earning Date
- INSI 01-01-0001
- CLLS 11-04-2024
- Dividend Yield
- INSI 4.90%
- CLLS N/A
- EPS Growth
- INSI N/A
- CLLS N/A
- EPS
- INSI N/A
- CLLS N/A
- Revenue
- INSI N/A
- CLLS $36,042,000.00
- Revenue This Year
- INSI N/A
- CLLS $387.77
- Revenue Next Year
- INSI N/A
- CLLS $11.14
- P/E Ratio
- INSI N/A
- CLLS N/A
- Revenue Growth
- INSI N/A
- CLLS 46.96
- 52 Week Low
- INSI $14.28
- CLLS $1.41
- 52 Week High
- INSI $16.40
- CLLS $3.38
- Technical
- Relative Strength Index (RSI)
- INSI 48.17
- CLLS 38.66
- Support Level
- INSI $16.96
- CLLS $1.65
- Resistance Level
- INSI $17.25
- CLLS $2.23
- Average True Range (ATR)
- INSI 0.24
- CLLS 0.18
- MACD
- INSI 0.02
- CLLS -0.03
- Stochastic Oscillator
- INSI 60.27
- CLLS 8.54
About INSI Insight Select Income Fund
Insight Select Income Fund is a diversified closed-end, management investment company. The fund's investment objective is to seek a high rate of return, primarily from interest income and trading activity, from a portfolio principally consisting of debt securities. It offers various solutions such as risk management, liquidity management, and return generation among others.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.